Recruiting

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

ClinicalTrials.gov IDNCT06972732

PhasePHASE4

Enrollment204

SponsorBoryung Pharmaceutical Co., Ltd

Age19 Years

SexALL

I'm interested View official listing

Conditions studied

Type 2 Diabetes

About this study

Interventions

Drug: Metformin — The dosage and dose frequency are maintained as they were before the screening.
Drug: Dapagliflozin/Pioglitazone — Dapagliflozin 10mg/Pioglitazone 30mg QD
Drug: Dapagliflozin/Sitagliptin — Dapagliflozin 10mg/Sitagliptin 100mg QD

Primary outcomes

HbA1c (%) change at 24 weeks compared to the baseline (Visit 2) (From baseline to end of treatment at 24 weeks)

Eligibility information

Inclusion Criteria: * Has voluntarily agreed to participate in this clinical trial. * Adults over 19 years of age * Diagnosed with type 2 diabetes Exclusion Criteria: * Has severe renal and liver disorders * Has type 1 diabetes * Those who are participating or have participated in other clinical trials and administered their investigational products within 8 weeks before the screening date for this study * Those who are deemed ineligible to participate in the study by the investigator

Study locations

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seocho District 06591 South Korea

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.